Human genes: RPLPO, ribosomal protein, large, P0; PPIA, peptidylprolyl isomerase A (cyclophilin A); TNFRSF1A, tumor necrosis factor receptor superfamily, member 1A; CCL11, CCL17, CCL19, CCL22, CCL3, CCL4, chemokine (C-C motif) ligand 11, 17, 19, 22, 3, and 4; CL5 chemokine (C-C motif) ligand 5; CCR1, CCR7, CCR8, chemokine (C-C motif) receptor 1, 7, and 8; CD86
molecule; CXCL12, chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); CXCL2, chemokine (C-X-C motif) ligand 2; CXCR4, chemokine (C-X-C motif) receptor 4; L128, interleukin 12B (natural killer cell-stimulating factor 2, cytotoxic lymphocyte maturation factor 2, p40); IL15, IL4, IL8, interleukin 15, 4, and 8; HPRT1, hypoxanthine phosphoribosyltransferase 1; PGK1, phosphoglycerate kinase 1.
El fenotipo clasico de las DC maduras incluye una expresion de alta densidad en la superficie de CD40, CD83, moleculas coestimuladoras (CD80 y CD86
) y el receptor de quimiocinas CCR7 (5).
"The use of CpG oligos allows the generation of mature dendritic cells from the peripheral blood within two days." He also stated, "The combination of CpG and GM-CSF is synergistic for the induction of other critical co-stimulatory molecules on the surfaces of dendritic cells required for their function including CD86
They are poor antigen-presenting cells; do not express MHC class II or the costimulatory molecules CD40, CD40L, CD80, and CD86
[10, 11]; and are not prone to undergo malignant transformation [12, 13].
In all cases, we have observed an increase in the expression of surface markers F4/80 and CD86
and an enhanced secretion of cytokines IL-23 and TNF-[alpha] (Figure 1).
It has been well established that CD80 (or B7-1) and CD86
(or B7-2) are crucial costimulatory molecules in T cell activation, inducing Th1 and Th2 differentiation, respectively, in host immune responses.
MMP-13-silenced DCs and control DCs were analyzed for surface expression of CD80 and CD86
and phagocytosis capability using flow cytometry.
DC activation by sensitizers causes the upregulation of costimulatory molecules such as CD86
(Linsley et al., 1991), CD54 (Grakoui et al., 1999; Comrie et al., 2015), and other surface molecules (reviewed by Hubo et al., 2013) that are involved in antigen presentation.
In this process, DCs undergo significant changes in the expression of the many molecules through which they interact with T cells, including CD86
, CD40, CD134/OX40L, and several chemokine receptors (Steinman 2003).
Interaction of lipopolysaccharide-stimulated polymorphonuclear (LPS-PMN) cells with DCs leads to upregulation of DC CD40, CD80, major histocompatibility complex (MHC) class II, and CD86
surface molecules, either by secreted soluble factors such as tumor necrosis factor (TNF)-[alpha], or by cell-to-cell contact.
Cell suspensions were stained with the following appropriately labeled antibodies: CD11b, Ly6G- Ly6C, CD4, CD25, Foxp3, mPDCA-1, CD11c, CD115, MHC-II, CD80, and CD86
(BD Biosciences, Pont de-Claix, France).
The activation of macrophages through PRR receptors induces the expression of major histocompatibility complex (MHC) class II and costimulatory molecules such as CD40, CD80, and CD86
, which are critical for T cell activation .